NVS
Novartis AGHealthcare · $260.7B market cap
Verdict
Share price
$141.00
close of Oct 3, 2026
Fair value
$123.75
Sticker Price
Payback Price
$49.50
buy price
NVS is Overpriced: at $141.00 it trades 14% above its fair value of $123.75. Its buy price (Payback Price) is $49.50, 65% below today's price. Business quality is limited: only 1 of 5 key numbers clears the 10% bar.
How we valued it
Owner Earnings. Earnings grow slowly (under 7% a year), but cash flow is steady, so we value it on its cash flow instead of its earnings.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow NVS
Get notified when it reaches its buy price of $49.50. Free.
Create a free accountSuperinvestors
4 of the investors we track hold NVS. In Q2 2026, 1 added and 1 trimmed. Who we track
About Novartis AG
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is…
Drug Manufacturers - General
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works